| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 65026 |
cas:644981-35-1 Val-Cit-PAB-MMAE |
67 |
zyl |
2024-12-19 |
| 65027 |
cas:170908-81-3，DOTA-NHS ester ，1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸 1-(2,5-二氧代-1-吡咯烷基)酯 |
62 |
kx |
2024-12-19 |
| 65028 |
endo-BCN-PEG4-Val-Cit-PAB-MMAE的介绍 |
72 |
zyl |
2024-12-19 |
| 65029 |
cas:2259318-50-6，MA-PEG4-VA-PBD ， ADC试剂 |
85 |
kx |
2024-12-19 |
| 65030 |
CAS: 2259318-55-1 - DBCO-(PEG2-VC-PAB-MMAE)2 |
57 |
WYQ |
2024-12-19 |
| 65031 |
CAS: 2768446-73-5，DBCO-Val-Cit-PAB-MMAE |
69 |
WYQ |
2024-12-19 |
| 65032 |
MC-vc-PAB-C6-a-amanitin， ADC试剂 |
59 |
kx |
2024-12-19 |
| 65033 |
cas:663598-98-9，2,5-dioxopyrrolidin-1-yl 4-methyl-4-((5-nitropyridin-2-yl)disulfanyl)pentanoate，ADC定制 |
75 |
wyh |
2024-12-19 |
| 65034 |
cas:2873452-49-2 MC-EVCit-PAB-MMAE |
77 |
zyl |
2024-12-19 |
| 65035 |
2,5-dioxopyrrolidin-1-yl 3-methyl-3-(pyridin-2-yldisulfanyl)butanoate，ADC定制 |
86 |
wyh |
2024-12-19 |
| 65036 |
cas:159857-70-2 MC-Val-Cit-Doxorubicin |
108 |
zyl |
2024-12-19 |
| 65037 |
Gly3-vc-PAB-MMAE， ADC试剂 |
85 |
kx |
2024-12-19 |
| 65038 |
CAS: 1869126-64-6， Azido-PEG4-Val-Cit-PAB-MMAE |
68 |
WYQ |
2024-12-19 |
| 65039 |
cas:2353409-54-6 ， Mal-amido-PEG8-Val-Gly，ADC定制 |
81 |
wyh |
2024-12-19 |
| 65040 |
Azido-PEG4-Val-Ala-PAB-PNP |
84 |
zyl |
2024-12-19 |
| 65041 |
NOTA-(NGR)2 NOTA偶联NGR二聚体 |
71 |
h |
2024-12-19 |
| 65042 |
1-(2,5-dioxopyrrolidin-1-yloxy)-4-((5-nitropyridin-2-yl)disulfanyl)-1-oxobutane-2-sulfonic acid，ADC定制 |
80 |
wyh |
2024-12-19 |
| 65043 |
CAS: 1343476-44-7，Val-Ala-PAB-OH |
68 |
WYQ |
2024-12-19 |
| 65044 |
MC-PBD， ADC试剂 |
77 |
kx |
2024-12-19 |
| 65045 |
Mal-Val-Ala-PAB的介绍 |
79 |
zyl |
2024-12-19 |
| 65046 |
DOTA-K-A9 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)结合肽A9 |
66 |
h |
2024-12-19 |
| 65047 |
Azide-PEG3-Val-Cit-PAB-MMAF，叠氮-三聚乙二醇-Val-Cit-PAB-MMAF |
67 |
WYQ |
2024-12-19 |
| 65048 |
Arm-DOTA-B72.3 |
67 |
h |
2024-12-19 |
| 65049 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
84 |
zyl |
2024-12-19 |
| 65050 |
(Lys(DOTA)4)BVD15 DOTA偶联神经肽Y(NPY)类似物 |
111 |
h |
2024-12-19 |
| 65051 |
1801838-28-7，Mc-vc-PAB-SN38，化合物MC-VC-PAB-SN38 |
73 |
kx |
2024-12-19 |
| 65052 |
DOTA-PPI 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)-官能化的聚(丙烯亚胺)(PPI)糖树枝状分子 |
75 |
h |
2024-12-19 |
| 65053 |
CAS: 863971-17-9，MC-Val-Cit-PAB-MMAF |
97 |
WYQ |
2024-12-19 |
| 65054 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
114 |
zyl |
2024-12-19 |
| 65055 |
DBCO-PEG4-vc-PAB-MMAE， ADC试剂 |
95 |
kx |
2024-12-19 |
| 65056 |
1884578-00-0，Boc-PEG4-Val-Ala-PAB-PNP，ADC定制 |
98 |
wyh |
2024-12-19 |
| 65057 |
DOTA-Peg-Cpa-c[DCys-Aph(Cbm)-DTrp-Lys-Thr-Cys]-2Nal-NH2 |
68 |
h |
2024-12-19 |
| 65058 |
DOTA-2.5D DOTA-胱氨酸结肽(knottins)2.5D和2.5F |
78 |
h |
2024-12-19 |
| 65059 |
二苯并环辛炔-四聚乙二醇-VAL-ALA-PAB，ADC定制 |
105 |
wyh |
2024-12-19 |
| 65060 |
Hz220(DOTA-Lys(IR dye 650)-PEa(4)-[D-Phe(6)DOTA偶联的GRPr拮抗剂 |
81 |
h |
2024-12-19 |
| 65061 |
Azido-PEG4-MMAE，抗体药物偶联物（ADCs） |
111 |
WYQ |
2024-12-19 |
| 65062 |
1626359-62-3，SPDB-DM4， ADC试剂 |
69 |
kx |
2024-12-19 |
| 65063 |
Acid-PEG4-Val-Cit-PAB-MMAE，包含PEG链和MMAE等部分 |
76 |
WYQ |
2024-12-19 |
| 65064 |
cas:159857-70-2，MC-Val-Cit-Doxorubicin，ADC定制 |
97 |
wyh |
2024-12-19 |
| 65065 |
DOTA-(D)Phe(1)-Tyr(3) |
74 |
h |
2024-12-19 |
| 65066 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
114 |
zyl |
2024-12-19 |
| 65067 |
FAM-amido hexamethylene carbamate-PAB-Cit-Val-Alkyne |
111 |
WYQ |
2024-12-19 |
| 65068 |
DOTA-l-Nal3-octreotide DOTA-l-nal3-奥曲肽 |
70 |
h |
2024-12-19 |
| 65069 |
CAS: 2762518-86-3 ，NHS ester-PEG4-Val-Cit-PAB-MMAE |
79 |
WYQ |
2024-12-19 |
| 65070 |
cas:2873452-49-2 ； MC-EVCit-PAB-MMAE，ADC定制 |
98 |
wyh |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询